Farmer Dan

$IBRX Lynch syndrome carriers face up to 82% lifetime risk of colorectal cancer + multiple other malignancies. No great prevention options beyond constant surveillance & risky surgeries. Enter this groundbreaking Phase IIb trial (TRIAD5-Plus): Tri-Ad5 vaccines (CEA/MUC1/brachyury) + NAI (#ANKTIVA) — ImmunityBio’s IL-15 superagonist that supercharges NK cells & CD8+ T cells without expanding Tregs. Safety phases done. Well-tolerated. RCT fully enrolled. This is immune interception at the pre-cancer stage in genetically high-risk people. $IBRX isn’t just treating cancer - they’re engineering the future of preventing it in the most vulnerable. Multifaceted biotech renaissance in action.

@mrmikeMTL flavored seltzer

Those who cut out soda completely, what did you switch to?

Here's the Lynch syndrome paper from NCI. The trial is supported by the Cancer Prevention—Clinical Trials Network (CP-CTNet), a grant-funded network from the National Cancer Institute’s (NCI) Division of Cancer Prevention (DCP) that performs early-phase cancer prevention clinical trials. This trial represents the first cross-network trial performed by all five grant recipients and their affiliated organizations, at a total of 16 study sites. As stated by the authors: "Our trial employs a vaccination strategy that addresses common reasons for vaccine failure by targeting multiple antigens, using a proven adenoviral delivery system, and studying an immune-competent high-risk population without active cancer." frontiersin.org/journals/immun…

NANT Leonardo landed in California and cleared customs! Assembly begins next week of the world's first AI driven cell manufacturing robot.

@LoriMills4CA42 @bullishbruk @DrPatrick Hey @SecKennedy @DrOz, how many more patients with Glioblastoma have to suffer and die before this therapy is approved?

@US_FDA Unlease Anktiva

@US_FDA cut the red tape! Give this cancer patient the right to access #ANKTIVA! Your requirements for trials is killing people! @bullishbruk

$IBRX Our good Dr’s Sunday morning post is not subtle. Cancer immunotherapy is moving toward stronger, more scalable platforms, and Patrick is pointing right at NK cell stimulation, cancer vaccines, and prevention. The Lynch Syndrome trial readout next year could be a major one. This is not just bladder cancer anymore. The platform story keeps getting bigger.

Which one is going to get her more excited? Which one would you rather drive?

@TheRealJFeld I prefer the 1950s

The Ferrari Luce will likely do quite well and the LoveFrom team is beyond talented. I’m sure the passenger experience will be phenomenal. However, I was hoping to get something a little more BatMobile-y.

@ClarksonsFarm1 What say you?

@Kshi_nippon Works in rural Pennsylvania as well

One thing many foreigners find unbelievable about Japan 🇯🇵 In some rural areas, people sell vegetables through unmanned stands. No staff. No security guard. You simply take what you want and leave the money behind. And somehow… it often works. Could this exist in your country?

@yitong Enzo is rolling over in his grave

rivers of ink will be spilled about the Luce design but my biggest gripe with it is that it's clearly made by people with no rage in their heart, and no sex in their veins ferrari is about love and anger in a way that wholesome california design bois will never understand

@coopernicus01 Not completely destroyed. That will happen when @TSLA rolls out its Roadster.

ferrari just lost all their aura, it’s over. brand destroyed, just like when jaguar made that pink car and lost 99% of profit.

@elonmusk @RobertKennedyJc @DrOz Please help ImmunityBio, El Segundo, CA get the message out to people suffering from bladder cancer, lung cancer, brain cancer, even sepsis, among other maladies. FDA is moving ever so slowly. Saudi Arabia, Portugal, Macau and others are way ahead of us. Someday when you are at SpaceX Hawthorne, stop by. Support your countryman, Dr. Patrick and the ImmunityBio Team, with our mission to help alleviate the suffering. CSSIFM.org 15,000 are praying for our help. More each day. We could also use a squeeze on the insidious shorts pressuring our stock. Almost Ready to blastoff at scale. Medical miracle, unstoppable. Everyone read the Quilt studies and decide for yourself. @DavidDin @bullishbruk @Deepvalue69420 @bluefinsashimi @LoriMills4CA42 @mckenzielaw @SAAS1975 @SAAS1975 @EricTrump @joerogan @joeroganhq @VDHanson @bennyjohnson @BarronTNews_ @DanScavino

@SamaHoole That sounds about right. People in a distant city making rules about something they have no clue about

A farmer dies in April 2026. His son inherits the farm. The farm has been in the family since 1847. The farm consists of: 300 acres of grazing pasture, a farmhouse built in 1892, a barn, a milking parlour, two tractors of varying ages, a Land Rover that runs about 70% of the time, and a herd of 180 Hereford-cross cattle. On paper, the farm is worth approximately £3.2 million. This is because land near him has been bought recently by a London hedge fund looking for carbon credits, which has dragged the comparable value of every field within forty miles upward to a number nobody local can justify. In cash, the farm produces a profit of about £28,000 a year in a good year. In a bad year it loses money. The son also works as a fencing contractor three days a week to keep the operation viable. The inheritance tax bill on a £3.2 million estate, even at the reduced 20% rate, comes to approximately £140,000 after the increased threshold is applied. The son does not have £140,000. The son has never had £140,000. The son has £4,200 in his current account and an overdraft. The son sells 60 acres to a developer to pay the tax. The developer puts solar panels on the 60 acres. The remaining herd cannot be sustained on the reduced land. The herd is sold. The barn becomes a holiday let. A different family eats Brazilian beef this Christmas without knowing why the price went up. The Treasury collects £140,000. The land never produces British food again.

@bullishbruk @FDAOncology True

You might be wondering why I keep bringing $MRK @FDAOncology FDA’s Jan 6, 2027 PDUFA for $IBRX ANKTIVA sBLA (papillary-only NMIBC, no CIS) delays access for ~85% of patients despite data from same QUILT-3.032 trial as 2024 CIS approval — likely to protect Merck Keytruda’s BCG-unresponsive bladder cancer franchise. Patient Need: High-risk papillary patients require bladder-sparing therapy now to avoid recurrence/cystectomy; delay leaves reliance on limited options like Keytruda. • Keytruda Position: Approved 2020 for CIS ± papillary; dominates immuno-oncology revenue in bladder cancer. ANKTIVA expansion would compete directly. • Timeline Issues: FDA RTF + data requests (2025–2026) led to standard (not priority) review; creates 2.5+ year gap favoring Merck (BigPharma) over ImmunityBio. It is all by design slow walking it. Your thoughts? @LoriMills4CA42 @DrPatrick

$IBRX ImmunityBio（$IBRX）在ASCO 2026會議公布的復發性膠質母細胞瘤（GBM）治療突破，使用無化療組合NAI（Nogapendekin alfa inbakicept）+ PD-L1 t-haNK + bevacizumab，達成首例影像學完全緩解。 QUILT-3.078試驗中，14名患者接受每兩週治療，中位追蹤6.75個月後總存活期尚未達到，淋巴細胞計數上升，無CRS或ICANS等嚴重免疫相關毒性。 此為首個報導此類CAR-NK細胞與IL-15激動劑組合在復發GBM的臨床反應，支持針對標準治療引起的淋巴細胞減少進行免疫重建，目前Phase 2B擴大試驗持續進行中。

Glioblastoma is a very aggressive cancer. $ibrx registered a 1st here

$IBRX at #ASCO26: First complete response in recurrent GBM with chemo-free regimen (NAI + PD-L1 t-haNK + bev). Median OS not reached (6.75 mo f/u). No CRS/ICANS. Big hope for brain cancer. 👍👍 #BrainCancer